Critical Analysis: Mangoceuticals (NASDAQ:MGRX) & Lyell Immunopharma (NASDAQ:LYEL)

Lyell Immunopharma (NASDAQ:LYEL) and Mangoceuticals (NASDAQ:MGRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Lyell Immunopharma and Mangoceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1	0	2	0	2.33
Mangoceuticals	1	0	0	0	1.00

Lyell Immunopharma currently has a consensus price target of $39.50, indicating a potential upside of 86.23%. Given Lyell Immunopharma’s stronger consensus rating and higher probable upside, analysts clearly believe Lyell Immunopharma is more favorable than Mangoceuticals.

Risk & Volatility

Lyell Immunopharma has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500. Comparatively, Mangoceuticals has a beta of 2.54, meaning that its stock price is 154% more volatile than the S&P 500.

Institutional & Insider Ownership

66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are held by institutional investors. 22.3% of Lyell Immunopharma shares are held by company insiders. Comparatively, 16.0% of Mangoceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Lyell Immunopharma and Mangoceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$36,000.00	13,731.71	-$274.45 million	($16.30)	-1.30
Mangoceuticals	$460,000.00	11.97	-$8.71 million	($3.56)	-0.09

Mangoceuticals has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Lyell Immunopharma and Mangoceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-762,355.56%	-90.52%	-70.22%
Mangoceuticals	-4,253.43%	-114.63%	-106.42%

Summary

Lyell Immunopharma beats Mangoceuticals on 8 of the 14 factors compared between the two stocks.

About Lyell Immunopharma

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

About Mangoceuticals

Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.